Mayukh Das

1.7k total citations
49 papers, 1.1k citations indexed

About

Mayukh Das is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Mayukh Das has authored 49 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 13 papers in Immunology. Recurrent topics in Mayukh Das's work include Vibrio bacteria research studies (10 papers), Lung Cancer Treatments and Mutations (10 papers) and Colorectal Cancer Treatments and Studies (9 papers). Mayukh Das is often cited by papers focused on Vibrio bacteria research studies (10 papers), Lung Cancer Treatments and Mutations (10 papers) and Colorectal Cancer Treatments and Studies (9 papers). Mayukh Das collaborates with scholars based in United States, United Kingdom and India. Mayukh Das's co-authors include D. Ferry, Carla Visseren‐Grul, Yvonne Summers, T. Benepal, J. Cadranel, Fiona Maxwell, Rohit Lal, Daniel C. Christoph, Ry Young and Carlos F. Gonzalez and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Mayukh Das

45 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mayukh Das United States 15 363 361 194 162 150 49 1.1k
Yvonne Braun Germany 22 214 0.6× 555 1.5× 293 1.5× 46 0.3× 44 0.3× 43 1.4k
Daan van den Broek Netherlands 22 502 1.4× 494 1.4× 426 2.2× 67 0.4× 82 0.5× 87 1.5k
B. Roche France 17 140 0.4× 541 1.5× 68 0.4× 72 0.4× 48 0.3× 39 1.4k
Marek Rusin Poland 21 366 1.0× 1.1k 3.1× 107 0.6× 159 1.0× 87 0.6× 49 1.5k
Simon Waters United Kingdom 15 322 0.9× 407 1.1× 286 1.5× 35 0.2× 67 0.4× 31 941
Jae Yun Lim South Korea 24 441 1.2× 1.0k 2.8× 405 2.1× 44 0.3× 102 0.7× 62 1.9k
Michael J. Ellis United Kingdom 22 361 1.0× 540 1.5× 547 2.8× 119 0.7× 51 0.3× 61 1.8k
Francesca Andreoni Italy 18 344 0.9× 435 1.2× 215 1.1× 149 0.9× 119 0.8× 50 1.3k
Alexandra Thiele Germany 16 230 0.6× 779 2.2× 517 2.7× 34 0.2× 52 0.3× 32 1.3k
Fenglin Li China 17 112 0.3× 500 1.4× 55 0.3× 176 1.1× 145 1.0× 98 986

Countries citing papers authored by Mayukh Das

Since Specialization
Citations

This map shows the geographic impact of Mayukh Das's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mayukh Das with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mayukh Das more than expected).

Fields of papers citing papers by Mayukh Das

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mayukh Das. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mayukh Das. The network helps show where Mayukh Das may publish in the future.

Co-authorship network of co-authors of Mayukh Das

This figure shows the co-authorship network connecting the top 25 collaborators of Mayukh Das. A scholar is included among the top collaborators of Mayukh Das based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mayukh Das. Mayukh Das is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Algazi, Alain P., Kyriakos P. Papadopoulos, Frank Tsai, et al.. (2024). Safety and clinical activity of durvalumab combined with tremelimumab in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase I study. ESMO Open. 9(8). 103646–103646. 4 indexed citations
2.
Tran, Ben, Mark Voskoboynik, Johanna C. Bendell, et al.. (2024). A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors. Immunotherapy. 16(11). 759–774. 5 indexed citations
3.
Goiri, Íñigo, Esha Choukse, Mayukh Das, et al.. (2024). SmartOClock: Workload- and Risk-Aware Overclocking in the Cloud. 437–451. 3 indexed citations
4.
Patel, Sandip Pravin, Teresa Alonso‐Gordoa, Susana Banerjee, et al.. (2024). Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 12(2). e007340–e007340. 25 indexed citations
5.
Hameed, B. M. Zeeshan, Mayukh Das, Nithesh Naik, et al.. (2023). Revolutionizing Organ Donation With Blockchain Technology. 2(5). 31–38.
6.
Lim, Emerson A., Johanna C. Bendell, Gerald S. Falchook, et al.. (2022). Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors. Clinical Cancer Research. 28(22). 4871–4884. 55 indexed citations
7.
Behl, Tapan, Aayush Sehgal, Sukhbir Singh, et al.. (2021). Anticipated pharmacological role of Aviptadil on COVID-19. Environmental Science and Pollution Research. 29(6). 8109–8125. 9 indexed citations
8.
Pegram, Mark D., Erika Hamilton, Antoinette R. Tan, et al.. (2021). First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer. Molecular Cancer Therapeutics. 20(8). 1442–1453. 73 indexed citations
9.
Das, Mayukh, et al.. (2018). Isolation and characterization of novel broad host range bacteriophages of Vibrio cholerae O1 from Bengal. Journal of Global Infectious Diseases. 10(2). 84–84. 5 indexed citations
10.
Fuchs, Charles S., Josep Tabernero, Atsushi Ohtsu, et al.. (2017). Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. Annals of Oncology. 28(12). 2932–2942. 82 indexed citations
11.
Summers, Yvonne, J. Cadranel, T. Benepal, et al.. (2016). Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treatment Reviews. 44. 42–50. 311 indexed citations
12.
Das, Mayukh, et al.. (2016). Transmission of phage by glassy-winged sharpshooters, a vector ofXylella fastidiosa. PubMed. 6(3). e1218411–e1218411. 5 indexed citations
13.
14.
15.
Nicolson, M., Dean A. Fennell, David Ferry, et al.. (2013). Thymidylate Synthase Expression and Outcome of Patients Receiving Pemetrexed for Advanced Nonsquamous Non–Small-Cell Lung Cancer in a Prospective Blinded Assessment Phase II Clinical Trial. Journal of Thoracic Oncology. 8(7). 930–939. 49 indexed citations
16.
Das, Mayukh, et al.. (2011). Vibrio cholerae Typing Phage N4: Genome Sequence and Its Relatedness to T7 Viral Supergroup. Intervirology. 55(3). 185–193. 6 indexed citations
17.
Wiseman, Daniel H., Mayukh Das, Kay Poulton, & Effie Liakopoulou. (2010). Donor cell leukemia following unrelated donor bone marrow transplantation for primary granulocytic sarcoma of the small intestine. American Journal of Hematology. 86(3). 315–318. 8 indexed citations
18.
Das, Mayukh, et al.. (2010). Evaluation ofVcAVNTR as a strain-typing and phylogeny study method ofVibrio choleraestrains. Epidemiology and Infection. 138(11). 1637–1649. 5 indexed citations
19.
Das, Mayukh, et al.. (2006). Phenotypic and molecular typing of Vibrio cholerae O1 and O139 isolates from India. Journal of Infection. 54(5). 475–482. 19 indexed citations
20.
Das, Mayukh, et al.. (2003). Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia. Bone Marrow Transplantation. 32(2). 125–129. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yvonne Braun Breakdown of academic impact, for papers by Daan van den Broek Breakdown of academic impact, for papers by B. Roche Breakdown of academic impact, for papers by Marek Rusin Breakdown of academic impact, for papers by Simon Waters Breakdown of academic impact, for papers by Jae Yun Lim Breakdown of academic impact, for papers by Michael J. Ellis Breakdown of academic impact, for papers by Francesca Andreoni Breakdown of academic impact, for papers by Alexandra Thiele Breakdown of academic impact, for papers by Fenglin Li
Rankless by CCL
2026